CNCE earnings

Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update. To join the live call to ask questions, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of the call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months. About Concert

CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at 8:30 a.m. ET; Online Registration Required to Access Dial in and PIN for Live Call to Ask Questions Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the second quarter of 2022. "We are very happy to have seen consistent efficacy and safety results across our two Phase 3 clinical trials of CTP-543 in alopecia areata. The positive results that we reported from THRIVE-AA1 in May and from THRIVE-AA2 earlier this week

New Online Registration Required for Live Call to Ask Questions Audio-Only Webcast Still Available on Concert's Website Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the second quarter of 2022, on Thursday, August 4, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a business update. Please note that there is a new system to access the live call in order to ask questions. To join the live call, please register here. A dial in and unique PIN will be provided to join the call. An audio-only webcast of

Phase 3 Data Readout in Alopecia Areata Expected Second Quarter of 2022 Alopecia Areata Represents Significant Market Opportunity with Important Medical Need Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the first quarter of 2022. "We are at an exciting point in our progress with CTP-543, our drug candidate for alopecia areata, a serious autoimmune disorder with significant unmet medical need. Our pivotal trials, THRIVE-AA1 and THRIVE-AA2, have collectively enrolled over 1,200 patients in the U.S., Canada and Europe. We're grateful to the many individuals who chose to participate in our studies to advance

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the first quarter of 2022, on Thursday, May 5, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its first quarter 2022 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast of the conference call may be accessed in the Investors section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled w

Two Phase 3 Registrational Clinical Trials Fully Enrolled for CTP-543 for the Treatment of Alopecia Areata CTP-543 THRIVE-AA1 Phase 3 Trial Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial Topline Data Expected Third Quarter of 2022 Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2021. "Our team is extremely proud and motivated by our success in enrolling more than 1,200 patients in our THRIVE-AA Phase 3 program in line with our projected timelines. This represents a significant milestone for Concert as we focus on commercializing CTP-543 to help mee

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the fourth quarter of 2021, on Thursday, March 3, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its fourth quarter 2021 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast of the conference call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months.

CTP-543 THRIVE-AA1 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Fully Enrolled with Topline Data Expected Second Quarter of 2022 CTP-543 THRIVE-AA2 Phase 3 Trial in Patients with Moderate to Severe Alopecia Areata Progressing with Topline Data Expected Second Half of 2022 CTP-543 Treatment Shows Maintenance of Hair Regrowth in Open Label Extension Trial Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2021. "The CTP-543 pivotal program is progressing on track to support an NDA filing with the FDA in early 2023," said Roger Tung, Ph.D., President and Chief Executive

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its financial results for the third quarter of 2021, on Tuesday, November 9, 2021, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2021 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast of the conference call may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay of the webcast will be available on Concert's website for three months.

CTP-543 Phase 3 Program On Track to Support NDA Filing in Early 2023 Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the second quarter of 2021. "Our development priority is to advance CTP-543 through its pivotal trials for alopecia areata in support of a planned early 2023 New Drug Application. We remain on track with our clinical progression of CTP-543, a drug candidate with the potential to address an important unmet medical need and sizeable market opportunity," said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. "Alopecia areata is a chronic autoimmune disease with